Cargando…

Alternative dosing of dual PI3K and MEK inhibition in cancer therapy

BACKGROUND: PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are thought to be the central transducers of oncogenic signals in solid malignancies, and there has been a lot of enthusiasm for developing inhibitors of these pathways for cancer therapy. Some preclinical models have suggested that combining in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jokinen, Elina, Laurila, Niina, Koivunen, Jussi P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563486/ https://www.ncbi.nlm.nih.gov/pubmed/23259591 http://dx.doi.org/10.1186/1471-2407-12-612

Ejemplares similares

Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features
por: Jokinen, Elina, et al.
Publicado: (2014)

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
por: Temraz, Sally, et al.
Publicado: (2015)

Dual blockade of PI3K and MEK in combination with radiation in head and neck cancer
por: Blas, Kevin, et al.
Publicado: (2018)

Dual inhibition of the MEK/ERK and PI3K/AKT pathways prevents pulmonary GVHD suppressing perivenulitis and bronchiolitis
por: Muranushi, Hiroyuki, et al.
Publicado: (2022)

Dual Targeting of MEK and PI3K Pathways Attenuates Established and Progressive Pulmonary Fibrosis
por: Madala, Satish K., et al.
Publicado: (2014)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells
por: Du, Wei, et al.
Publicado: (2021)

Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells()
por: Wu, Y. Linda, et al.
Publicado: (2017)

Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer
por: Toulany, Mahmoud, et al.
Publicado: (2016)

Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy
por: Chang, Raymond, et al.
Publicado: (2019)

K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo
por: Hofmann, Irmgard, et al.
Publicado: (2012)

Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs
por: Haas, Bodo, et al.
Publicado: (2018)

Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations
por: Rittler, Dominika, et al.
Publicado: (2020)

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
por: Li, Qingfang, et al.
Publicado: (2022)

In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC
por: Heavey, Susan, et al.
Publicado: (2016)

RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy
por: Yajima, Ichiro, et al.
Publicado: (2012)

A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
por: Ischenko, Irene, et al.
Publicado: (2015)

Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway
por: Ramakrishnan, Vijay, et al.
Publicado: (2012)

Leptin Inhibits Glucose Intestinal Absorption via PKC, p38MAPK, PI3K and MEK/ERK
por: El-Zein, Ola, et al.
Publicado: (2013)

Repression of CD24 surface protein expression by oncogenic Ras is relieved by inhibition of Raf but not MEK or PI3K
por: Pallegar, Nikitha K., et al.
Publicado: (2015)

Selective Eradication of Colon Cancer Cells Harboring PI3K and/or MAPK Pathway Mutations in 3D Culture by Combined PI3K/AKT/mTOR Pathway and MEK Inhibition
por: Atanasova, Velina S., et al.
Publicado: (2023)

Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines
por: Ma, Yixuan, et al.
Publicado: (2022)

RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells
por: Patel, Hima, et al.
Publicado: (2023)

Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells
por: Jin, W, et al.
Publicado: (2003)

DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties
por: Goulielmaki, Maria, et al.
Publicado: (2019)

eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK Inhibitors
por: Hijazi, Maruan, et al.
Publicado: (2022)

Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma
por: Wei, Bih‐Rong, et al.
Publicado: (2016)

Benzimidazoisoquinoline derivatives inhibit glioblastoma cell proliferation through down-regulating Raf/MEK/ERK and PI3K/AKT pathways
por: Zhang, Ya-Jun, et al.
Publicado: (2018)

Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR‐TKIs in non‐small cell lung cancer
por: Sato, Hiroki, et al.
Publicado: (2018)

Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1
por: Kurupi, Richard, et al.
Publicado: (2022)

Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells
por: Yuen, Hiu-Fung, et al.
Publicado: (2012)

Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical Models
por: Zhong, Hua, et al.
Publicado: (2013)

Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia
por: Wang, Xiang, et al.
Publicado: (2014)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
por: Chappell, William H., et al.
Publicado: (2011)

Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells
por: Burmi, Rajpal S., et al.
Publicado: (2018)

Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
por: Butler, Dominika E., et al.
Publicado: (2017)

Anti-tumor Activity of Bufalin by Inhibiting c-MET Mediated MEK/ERK and PI3K/AKT Signaling Pathways in Gallbladder Cancer
por: Qian, Liqiang, et al.
Publicado: (2020)

Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo
por: MIYOSHI, SEIGO, et al.
Publicado: (2012)

Correction: Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical Models
por: Zhong, Hua, et al.
Publicado: (2015)

Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer
por: Bhattacharya, Bhaskar, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3lpf8u2ertb52b8dddtoi2617g